{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T19:57:49Z","timestamp":1769630269397,"version":"3.49.0"},"reference-count":0,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2002,10,22]],"date-time":"2002-10-22T00:00:00Z","timestamp":1035244800000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2002,10]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The optimal dosing strategy for continuous intravenous furosemide infusion is unknown in pediatric patients. Eighteen patients less than 1 year old were studied after cardiac surgery during routine clinical care. The current strategy starts with a continuous infusion of 0.1 mg\/kg \u00b7 h, which may be adapted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A pharmacokinetic\u2010pharmacodynamic model was developed that linked furosemide dose to furosemide serum concentrations, renal function (creatinine clearance), and urine output. Various regimens were simulated that adapt according to urine production. The modified dosing schedule was prospectively tested in a subsequent population of 18 pediatric patients after cardiac surgery.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Data from the follow\u2010up study suggest that urine production is more controlled for the proposed regimen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Both the modeling and simulation results and the follow\u2010up study indicated that a bolus dose of 1 mg\/kg followed 6 hours later with a 1\u2010 or 2\u2010mg\/kg loading dose and a 0.2\u2010mg\/kg \u00b7 h intravenous infusion provides a rational starting point for furosemide therapy after cardiac surgery in pediatric patients less than 1 year old. Adjustment of this regimen every 12 hours in steps of 0.1 mg\/kg \u00b7 h on the basis of clinical assessment should lead to adequate control over urinary output.<\/jats:p><jats:p><jats:italic>Clinical Pharmacology &amp; Therapeutics<\/jats:italic> (2002) <jats:bold>72<\/jats:bold>, 383\u2013390; doi: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1067\/mcp.2002.127608\">10.1067\/mcp.2002.127608<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1067\/mcp.2002.127608","type":"journal-article","created":{"date-parts":[[2002,11,5]],"date-time":"2002-11-05T13:49:19Z","timestamp":1036504159000},"page":"383-390","source":"Crossref","is-referenced-by-count":13,"title":["Development of an optimal furosemide infusion strategy in infants with modeling and simulation"],"prefix":"10.1111","volume":"72","author":[{"given":"Rik C.","family":"Schoemaker","sequence":"first","affiliation":[{"name":"Centre for Human Drug Research and the Pediatric Intensive Care Unit Leiden University Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria M. J.","family":"van der Vorst","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research and the Pediatric Intensive Care Unit Leiden University Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle Ruijs\u2010Dudok","family":"van Heel","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research and the Pediatric Intensive Care Unit Leiden University Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam F.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research and the Pediatric Intensive Care Unit Leiden University Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacobus","family":"Burggraaf","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research and the Pediatric Intensive Care Unit Leiden University Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the Pediatric Pharmacology Network","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,10,22]]},"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1067\/mcp.2002.127608","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T10:03:39Z","timestamp":1700301819000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1067\/mcp.2002.127608"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["10.1067\/mcp.2002.127608"],"URL":"https:\/\/doi.org\/10.1067\/mcp.2002.127608","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10]]}}}